Morria Biopharmaceuticals Plc Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
4/21/2010 9:21:55 AM
LONDON & NEW YORK--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the initiation of its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study of up to 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied twice daily for 28 days, scored 69% improvement based on conventional Physician’s Assessment versus a standard 30% placebo effect generated by the vehicle. The upcoming study will examine a shortened b.i.d regime of 21 days as well as look at pharmacokinetics and dose-response parameters.
comments powered by